The U.S. Department of Justice (“DOJ”) announced its False Claims Act (“FCA”) enforcement statistics for FY 2023 and identified key priorities for FCA enforcement in 2024 and beyond. The DOJ continues to pursue FCA...more
3/8/2024
/ Compliance ,
Contractors ,
Coronavirus/COVID-19 ,
Cybersecurity ,
Department of Justice (DOJ) ,
Enforcement ,
False Billing ,
False Claims Act (FCA) ,
Federal Loans ,
Fraud ,
Healthcare Fraud ,
Incentives ,
Kickbacks ,
Medicare Fraud ,
Neither Admit Nor Deny Settlements ,
Opioid ,
Paycheck Protection Program (PPP) ,
Penalties ,
Treble Damages ,
Whistleblowers
In a second criminal case against a pharmaceutical distributor and its executives this year, the Department of Justice has accused Ohio-based Miami-Luken and its former President and Compliance Officer of conspiring to...more
9/6/2019
/ Controlled Substances ,
Criminal Prosecution ,
DEA ,
Department of Justice (DOJ) ,
Distributors ,
Drug & Alcohol Abuse ,
Government Investigations ,
Internal Controls ,
Opioid ,
Pharmacies ,
Physicians ,
Prescription Drugs ,
Unjust Enrichment
Rochester Drug Co-Operative, Inc. (“RDC”), one of the 10 largest pharmaceutical distributors in the United States, was recently charged along with its former Chief Executive Officer and former Chief Compliance Officer, for...more
5/28/2019
/ CCO ,
CEOs ,
Compliance ,
Controlled Substances ,
Controlled Substances Act ,
Corporate Executives ,
Criminal Conspiracy ,
Criminal Investigations ,
DEA ,
Deferred Prosecution Agreements ,
Drug Distribution ,
New Guidance ,
Opioid ,
Personal Liability ,
Pharmaceutical Industry ,
Pharmacies ,
Unlawful Distribution